Detalhe da pesquisa
1.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921541
2.
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
Br J Haematol
; 201(3): 411-416, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541031
3.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651883
4.
The black swan: a case of central nervous system graft-versus-host disease.
J Basic Clin Physiol Pharmacol
; 34(6): 805-809, 2023 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843253
5.
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
J Basic Clin Physiol Pharmacol
; 34(3): 401-404, 2023 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040263
6.
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.
Cancers (Basel)
; 15(22)2023 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001657
7.
Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis.
J Clin Med
; 11(7)2022 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35407474